首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >The prognostic utility of haptoglobin genotypes in squamous cell carcinoma of the head and neck.
【24h】

The prognostic utility of haptoglobin genotypes in squamous cell carcinoma of the head and neck.

机译:触珠蛋白基因型在头颈部鳞状细胞癌中的预后作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The aim of this study was to determine whether haptoglobin (Hp) genotypes are associated with prognosis in patients with squamous cell carcinoma of the head and neck (HNSCC). METHODS: We studied patients with HNSCC without distant metastasis at diagnosis. The Hp genotype of each patient was determined and the prognostic significance of the Hp genotype was further analyzed. Pearson's chi(2)-test or Fisher's exact test were used to analyze correlations between Hp genotype and clinical characteristics of HNSCC. Eighty patients with newly diagnosed HNSCC who were treated with curative modality were enrolled in this study. Kaplan-Meier plots and log-rank test were used to compare locoregional recurrence-free survival, distant-metastasis-free survival and overall survival of patients according to Hp genotype. Survival analysis was performed using Cox proportional hazard models. RESULTS: Eighty patients with newly diagnosed HNSCC were enrolled in this study. There was no significant difference in the distribution of Hp genotypes in HNSCC patients and healthy individuals (p=0.959). Matched-pair analysis showed that locoregional recurrence-free survival was poor (p=0.02) for HNSCC patients with Hp 2-2 or 2-0. There was no significant difference in distant metastasis-free survival and overall survival (p=0.422 and 0.509, respectively). Multivariate analysis showed that Hp 2-2 or 2-0 was associated with an increased risk of locoregional recurrence [Hazard ratio (HR) 5.9; 95% confidence interval (CI), 1.1-6.65; p=0.038]. The risk was still higher in patients with Hp 2-2 or 2-0 after further adjusting for age and treatment modality (HR 7.6; 95% CI, 1.2-46; p=0.028) in locoregional recurrence-free survival. CONCLUSIONS: The present data show that the Hp genotype is closely related to recurrence rate in patients with HNSCC. Patients with Hp 2-2 or 2-0 have greater locoregional recurrence and significantly increased HRs in multivariate analysis. The Hp genotype may be a prognostic factor in patients with HNSCC.
机译:背景:本研究的目的是确定触珠蛋白(Hp)基因型是否与头颈部鳞状细胞癌(HNSCC)患者的预后相关。方法:我们研究了在诊断时没有远处转移的HNSCC患者。确定每位患者的Hp基因型,并进一步分析Hp基因型的预后意义。皮尔逊的chi(2)检验或Fisher精确检验用于分析Hp基因型与HNSCC临床特征之间的相关性。本研究纳入了80例接受过治愈性治疗的新诊断为HNSCC的患者。根据Hp基因型,使用Kaplan-Meier图和对数秩检验比较患者的局部无复发生存率,远处无转移生存率和总生存率。使用Cox比例风险模型进行生存分析。结果:本研究纳入了80例新诊断的HNSCC患者。 HNSCC患者和健康个体中Hp基因型的分布没有显着差异(p = 0.959)。配对分析表明,Hp 2-2或2-0的HNSCC患者局部无复发生存率较差(p = 0.02)。远处无转移生存率和总生存率无显着差异(分别为p = 0.422和0.509)。多变量分析显示,Hp 2-2或2-0与局部复发的风险增加有关[危险比(HR)5.9; 95%置信区间(CI),1.1-6.65; p = 0.038]。在进一步调整年龄和治疗方式(HR 7.6; 95%CI,1.2-46; p = 0.028)后,Hp 2-2或2-0的患者在局部无复发生存中的风险仍然较高。结论:目前的数据表明Hp基因型与HNSCC患者的复发率密切相关。在多变量分析中,Hp 2-2或2-0的患者局部复发率更高,并且HRs显着增加。 Hp基因型可能是HNSCC患者的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号